WJP World Journal of Psychiatry

Submit a Manuscript: https://www.f6publishing.com

World J Psychiatry 2024 September 19; 14(9): 1411-1414

DOI: 10.5498/wjp.v14.i9.1411

ISSN 2220-3206 (online)

LETTER TO THE EDITOR

Burdened breaths: The influence of depression on obstructive sleep apnea

Xiao Wang, Shao-Ming Song, Hong-Mei Yue

Specialty type: Psychiatry

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification Scientific Quality: Grade C Novelty: Grade B Creativity or Innovation: Grade B Scientific Significance: Grade B

P-Reviewer: Zhang YH

Received: March 21, 2024 Revised: August 7, 2024 Accepted: August 13, 2024 Published online: September 19, 2024 Processing time: 173 Days and 9.5 Hours



Xiao Wang, Shao-Ming Song, Hong-Mei Yue, The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, Gansu Province, China

Corresponding author: Hong-Mei Yue, MD, PhD, Doctor, Professor, The First School of Clinical Medicine, Lanzhou University, No. 199 West Donggang Road, Lanzhou 730000, Gansu Province, China. yhmlcsy@163.com

Abstract

Depression and metabolic syndrome could exacerbate the risks of the other, leading to a series of severe coexisting conditions. One notable comorbidity that must be mentioned is obstructive sleep apnea (OSA). Current studies suggested that depression increases susceptibility to OSA. As the prevalence of depression rises, it becomes critical to prevent and manage its complications or comorbidities, including OSA. Predictive models, non-invasive electroencephalogram monitoring, genetic research, and other promising technologies are being applied to the prevention, diagnosis, and personalized treatment of depression and OSA.

Key Words: Depression; Obstructive sleep apnea; Metabolic syndrome; Prevalence; Risk factor

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Depression and obstructive sleep apnea frequently coexist and share similar symptoms. By exploring the causal relationship between depression and obstructive sleep apnea, we may gain new insights and develop strategies for their prevention and treatment, contributing to improved overall health status for these patients and promoting the development of personalized treatment approaches.

Citation: Wang X, Song SM, Yue HM. Burdened breaths: The influence of depression on obstructive sleep apnea. *World J Psychiatry* 2024; 14(9): 1411-1414 **URL:** https://www.wjgnet.com/2220-3206/full/v14/i9/1411.htm **DOI:** https://dx.doi.org/10.5498/wjp.v14.i9.1411

WJP | https://www.wjgnet.com

TO THE EDITOR

We read the retrospective cohort study published by Zhou et al[1] in the World Journal of Psychiatry in 2024. This study investigated the incidence and risk factors of depression among patients with metabolic syndrome (MetS). Subsequently, data from the 2-year, 4-year, and 7-year follow-up were analyzed to construct a predictive model for depression in patients with MetS. According to currently available studies, there is a strong relationship between depression and MetS. Zhou et al[1] described the causes and potential mechanisms associated with MetS and depression, and we believe that these results provide some insight into the causality of MetS and depression. However, the causality and direction of the two remains unclear due to the shortcomings of current observational study designs and the low feasibility of implementing randomized controlled trials[2,3].

Studies have shown that patients with depression were more likely to become obese or suffer from MetS due to lifestyle changes, sleep disorders, chronic inflammation, and the side effects of psychotropic medications[4,5]. Similarly, inflammation, imbalances in the neuroendocrine system, increased societal stress, poor lifestyle, and long-term medication render patients with MetS more susceptible to depression[6,7]. This suggests that the two conditions can exacerbate the risks of the other and lead to a series of severe coexisting diseases. One notable comorbidity that must be mentioned is obstructive sleep apnea (OSA)[8]. OSA is a common sleep disorder characterized by repeated episodes of upper airway collapse or obstruction, resulting in reduced or complete cessation of airflow during sleep[9]. OSA significantly affects sleep quality and physical health, leading to physical impairments and socioeconomic burdens. Longterm OSA increases the risk of heart disease, high blood pressure, and stroke[10,11].

Many studies have reported a strong association between depression and OSA, but most have focused on investigating the prevalence of depression among patients with OSA[12-16]. Using mendelian randomization analyses, our previously published study provided preliminary evidence that depression increases susceptibility to OSA[17]. Analyzing changes in nocturnal plasma levels of free fatty acids, glucose, and cortisol in patients with OSA, Chopra et al[18] found that patients with OSA and depression share increased sensitivity to corticotropin-releasing hormone, glucocorticoid resistance, and elevated cortisol levels due to similar hyperactivity of the hypothalamic-pituitary-adrenal axis and sympathetic nervous system. Furthermore, both depression and OSA have been shown to be associated with chronic inflammation and are characterized by higher levels of proinflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6[19,20].

Overall, the pathophysiological mechanisms of how depression contributes to OSA are not fully understood, but they may be related to several potential mechanisms as follows. Lifestyle and circadian rhythm changes could cause disruptions in sleep-wake rhythms, affecting the physiological balance of sleep and wake functions[21-23]. Depression is typically accompanied by hyperactivation of the hypothalamic-pituitary-adrenal axis; as adrenocorticotropic hormone secretion increases, patients may experience a decrease in slow-wave sleep duration and an increase in the average number of awakenings[24]. Moreover, impairment of the central and peripheral 5-hydroxytryptamine systems could affect airway patency. Reduced 5-hydroxytryptamine levels are thought to be one of the critical mechanisms leading to upper airway collapse and potentially to OSA[25].

As the prevalence of depression increases, it becomes critical to prevent and manage its complications or comorbidities such as OSA. Depression and OSA often coexist and exhibit similar symptoms, such as poor concentration, memory loss, mood swings, and unusual fatigue, which can complicate the clinical diagnosis of both conditions. Zhou et al[1] investigated the prevalence and risk factors of depression in patients with MetS and constructed predictive models through a large-sample cohort study. We believe this has significant implications, but there is no such model to predict the occurrence of OSA in depressed patients. For depressed patients, non-invasive electroencephalogram to detect susceptibility to OSA is a powerful tool [26]. Exploring the comorbidity and correlation between OSA and depression and understanding the prevalence in different populations could help identify high-risk groups and facilitate early intervention.

The treatment of OSA comorbid with depressive disorders involves various therapies for depression, including pharmacological and non-pharmacological interventions such as light therapy, sleep deprivation, and rhythm therapy. They have been shown to affect circadian rhythms. Oxidative stress and inflammation can also disrupt sleep architecture, contributing to dysfunctional sleep patterns^[27]. As the first-line treatment for OSA, studies have shown that continuous positive airway pressure therapy could improve depressive symptoms in patients over the long term, despite the presence of high heterogeneity. As more and more promising technologies are applied to depression and OSA, there will be opportunities to enhance our understanding of them and other comorbidities. The potential mechanisms may provide new ideas and strategies for the prevention and treatment of OSA and depression and help improve the overall health of such patients. However, current evidence largely depends on cross-sectional clinical data and a limited number of experimental results, which challenges the assertion that depression explicitly causes OSA.

FOOTNOTES

Author contributions: Wang X and Yue HM designed the study; Song SM searched the literature; Wang X and Yue HM wrote the manuscript; All authors approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to



distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/

Country of origin: China

ORCID number: Shao-Ming Song 0000-0001-8085-4476; Hong-Mei Yue 0009-0007-4999-8982.

S-Editor: Li L L-Editor: Filipodia P-Editor: Cai YX

REFERENCES

- Zhou LN, Ma XC, Wang W. Incidence and risk factors of depression in patients with metabolic syndrome. World J Psychiatry 2024; 14: 245-1 254 [PMID: 38464768 DOI: 10.5498/wjp.v14.i2.245]
- Repousi N, Masana MF, Sanchez-Niubo A, Haro JM, Tyrovolas S. Depression and metabolic syndrome in the older population: A review of 2 evidence. J Affect Disord 2018; 237: 56-64 [PMID: 29772477 DOI: 10.1016/j.jad.2018.04.102]
- Dekker IP, Marijnissen RM, Giltay EJ, van der Mast RC, Oude Voshaar RC, Rhebergen D, Rius Ottenheim N. The role of metabolic 3 syndrome in late-life depression over 6 years: The NESDO study. J Affect Disord 2019; 257: 735-740 [PMID: 31386966 DOI: 10.1016/j.jad.2019.07.060]
- Hiles SA, Révész D, Lamers F, Giltay E, Penninx BW. Bidirectional Prospective Associations of Metabolic Syndrome Components with 4 Depression, Anxiety, And Antidepressant Use. Depress Anxiety 2016; 33: 754-764 [PMID: 27120696 DOI: 10.1002/da.22512]
- Sekita A, Arima H, Ninomiya T, Ohara T, Doi Y, Hirakawa Y, Fukuhara M, Hata J, Yonemoto K, Ga Y, Kitazono T, Kanba S, Kiyohara Y. 5 Elevated depressive symptoms in metabolic syndrome in a general population of Japanese men: a cross-sectional study. BMC Public Health 2013; 13: 862 [PMID: 24044502 DOI: 10.1186/1471-2458-13-862]
- García-Toro M, Vicens-Pons E, Gili M, Roca M, Serrano-Ripoll MJ, Vives M, Leiva A, Yáñez AM, Bennasar-Veny M, Oliván-Blázquez B. 6 Obesity, metabolic syndrome and Mediterranean diet: Impact on depression outcome. J Affect Disord 2016; 194: 105-108 [PMID: 26807670 DOI: 10.1016/j.jad.2015.12.064]
- Moazzami K, Lima BB, Sullivan S, Shah A, Bremner JD, Vaccarino V. Independent and joint association of obesity and metabolic syndrome 7 with depression and inflammation. Health Psychol 2019; 38: 586-595 [PMID: 31120270 DOI: 10.1037/hea0000764]
- Lv R, Liu X, Zhang Y, Dong N, Wang X, He Y, Yue H, Yin Q. Pathophysiological mechanisms and therapeutic approaches in obstructive 8 sleep apnea syndrome. Signal Transduct Target Ther 2023; 8: 218 [PMID: 37230968 DOI: 10.1038/s41392-023-01496-3]
- Lévy P, Kohler M, McNicholas WT, Barbé F, McEvoy RD, Somers VK, Lavie L, Pépin JL. Obstructive sleep apnoea syndrome. Nat Rev Dis 9 Primers 2015; 1: 15015 [PMID: 27188535 DOI: 10.1038/nrdp.2015.15]
- 10 Sabil A, Gagnadoux F. Obstructive sleep apnoea, nocturnal hypoxaemia, and cognitive decline in elderly patients. Eur Respir J 2023; 61 [PMID: 37105589 DOI: 10.1183/13993003.00300-2023]
- Martinez-Garcia MA, Campos-Rodriguez F, Gozal D. Obstructive sleep apnoea in acute coronary syndrome. Lancet Respir Med 2020; 8: e15 11 [PMID: 32035024 DOI: 10.1016/S2213-2600(20)30040-0]
- 12 Fang H, Tu S, Sheng J, Shao A. Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med 2019; 23: 2324-2332 [PMID: 30734486 DOI: 10.1111/jcmm.14170]
- Gleeson M, McNicholas WT. Bidirectional relationships of comorbidity with obstructive sleep apnoea. Eur Respir Rev 2022; 31 [PMID: 13 35508332 DOI: 10.1183/16000617.0256-2021]
- Chen YH, Keller JK, Kang JH, Hsieh HJ, Lin HC. Obstructive sleep apnea and the subsequent risk of depressive disorder: a population-based 14 follow-up study. J Clin Sleep Med 2013; 9: 417-423 [PMID: 23674930 DOI: 10.5664/jcsm.2652]
- Lu MK, Tan HP, Tsai IN, Huang LC, Liao XM, Lin SH. Sleep apnea is associated with an increased risk of mood disorders: a population-15 based cohort study. Sleep Breath 2017; 21: 243-253 [PMID: 27495797 DOI: 10.1007/s11325-016-1389-x]
- 16 Lee SA, Paek JH, Han SH. REM-related sleep-disordered breathing is associated with depressive symptoms in men but not in women. Sleep Breath 2016; 20: 995-1002 [PMID: 26969657 DOI: 10.1007/s11325-016-1323-2]
- Wang X, Song S, Dong N, Lv R, He Y, Zhao Y, Yue H. The causal relationship between depression and obstructive sleep apnea: A 17 bidirectional Mendelian randomization study. J Psychosom Res 2024; 179: 111620 [PMID: 38430795 DOI: 10.1016/j.jpsychores.2024.111620]
- Chopra S, Rathore A, Younas H, Pham LV, Gu C, Beselman A, Kim IY, Wolfe RR, Perin J, Polotsky VY, Jun JC. Obstructive Sleep Apnea 18 Dynamically Increases Nocturnal Plasma Free Fatty Acids, Glucose, and Cortisol During Sleep. J Clin Endocrinol Metab 2017; 102: 3172-3181 [PMID: 28595341 DOI: 10.1210/jc.2017-00619]
- Gaines J, Vgontzas AN, Fernandez-Mendoza J, Kritikou I, Basta M, Bixler EO. Gender differences in the association of sleep apnea and 19 inflammation. Brain Behav Immun 2015; 47: 211-217 [PMID: 25535861 DOI: 10.1016/j.bbi.2014.11.013]
- Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between 20 schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016; 21: 1696-1709 [PMID: 26903267 DOI: 10.1038/mp.2016.3]
- 21 Gupta MA, Simpson FC, Lyons DC. The effect of treating obstructive sleep apnea with positive airway pressure on depression and other subjective symptoms: A systematic review and meta-analysis. Sleep Med Rev 2016; 28: 55-68 [PMID: 26454823 DOI: 10.1016/j.smrv.2015.07.002
- Holma IA, Holma KM, Melartin TK, Ketokivi M, Isometsä ET. Depression and smoking: a 5-year prospective study of patients with major 22 depressive disorder. Depress Anxiety 2013; 30: 580-588 [PMID: 23606190 DOI: 10.1002/da.22108]
- 23 Pandi-Perumal SR, Monti JM, Burman D, Karthikeyan R, BaHammam AS, Spence DW, Brown GM, Narashimhan M. Clarifying the role of sleep in depression: A narrative review. Psychiatry Res 2020; 291: 113239 [PMID: 32593854 DOI: 10.1016/j.psychres.2020.113239]
- 24 Eser D, Schüle C, Romeo E, Baghai TC, di Michele F, Pasini A, Zwanzger P, Padberg F, Rupprecht R. Neuropsychopharmacological



properties of neuroactive steroids in depression and anxiety disorders. Psychopharmacology (Berl) 2006; 186: 373-387 [PMID: 16247651 DOI: 10.1007/s00213-005-0188-z]

- 25 Liu C, Meng Z, Wiggin TD, Yu J, Reed ML, Guo F, Zhang Y, Rosbash M, Griffith LC. A Serotonin-Modulated Circuit Controls Sleep Architecture to Regulate Cognitive Function Independent of Total Sleep in Drosophila. Curr Biol 2019; 29: 3635-3646.e5 [PMID: 31668619 DOI: 10.1016/j.cub.2019.08.079]
- de Aguiar Neto FS, Rosa JLG. Depression biomarkers using non-invasive EEG: A review. Neurosci Biobehav Rev 2019; 105: 83-93 [PMID: 26 31400570 DOI: 10.1016/j.neubiorev.2019.07.021]
- Farney RJ, Lugo A, Jensen RL, Walker JM, Cloward TV. Simultaneous use of antidepressant and antihypertensive medications increases 27 likelihood of diagnosis of obstructive sleep apnea syndrome. Chest 2004; 125: 1279-1285 [PMID: 15078735 DOI: 10.1378/chest.125.4.1279]



Baishideng® WJP https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

